Current approaches to the treatment of hypertension in older persons

Postgraduate Medicine

Volumn 124, Issue 1, 2012, Pages 50-59

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

blockers; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive drugs; Calcium channel blockers; Diuretics; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; GUANETHIDINE; HYDRALAZINE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; MINOXIDIL; NEBIVOLOL; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; RESERPINE; TELMISARTAN; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; CORONARY ARTERY DISEASE; COUGHING; DEMENTIA; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ELECTROLYTE DISTURBANCE; FOLLOW UP; FRAIL ELDERLY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HIRSUTISM; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LUPUS LIKE SYNDROME; MORTALITY; MULTIINFARCT DEMENTIA; NEPHROSCLEROSIS; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESSORECEPTOR REFLEX; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SEDATION; SIDE EFFECT; SODIUM RESTRICTION; STROKE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VERY ELDERLY; WEIGHT REDUCTION;

AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; HEART FAILURE; HUMANS; HYPERTENSION; LIFE STYLE; MYOCARDIAL INFARCTION; PREVALENCE; STROKE; UNITED STATES;

EID: 84856831986     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.01.2517     Document Type: Article

References (115)

1. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
2. Waeber B, Banegas JR, Mancia G, Ruilope LM. Blood pressure control based on office and ambulatory blood pressure monitoring: the European experience in hypertensive patients treated in clinical practice. Arch Med Sci. 2009;5:351-358.
3. Lakatta EG. Mechanisms of hypertension in the elderly. J Am Geriatr Soc. 1989;37(8):780-790.
4. Gribbin B, Pickering GT, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res.1971;29(4):424-431.
5. Aronow WS. Dizziness and syncope. In: Hazzard WR, Blass JP, Ettinger WH Jr, Halter JB, Ouslander JG, eds. Principles of Geriatric Medicine and Gerontology. 4th ed. New York, NY: McGraw-Hill, Inc.; 1998:1519-1534.
6. Joseph J, Koka M, Aronow WS. Prevalence of moderate and severe renal insufficiency in older persons with hypertension, diabetes mellitus, coronary artery disease, peripheral arterial disease, ischemic stroke, or congestive heart failure in an academic nursing home. J Med Dir Assoc. 2008;9(4):257-259.
7. Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol. 2008;124(1): 6-21.
8. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157(21):2413-2446.
9. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci. 2002;57(1):M45-M46.
10. Mendelson G, Ness J, Aronow WS. Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47(5):597-599.
11. Koka M, Joseph J, Aronow WS. Adequacy of control of hypertension in an academic nursing home. J Am Med Dir Assoc. 2007; 8(8):538-540.
12. Joseph J, Koka M, Aronow WS. Prevalence of a hemoglobin A1c less than 7.0%, of a blood pressure less than 130/80 mm Hg, and of a serum low-density lipoprotein cholesterol less than 100 mg/dL in older patients with diabetes mellitus in an academic nursing home. J Am Med Dir Assoc. 2008;9(1):51-54.
13. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21-e181.
14. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program working group report on hypertension in the elderly. Hypertension. 1994;23(3):275-285.
15. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23(3):395-401.
16. Rigaud AS, Forette B. Hypertension in older adults. J Gerontol A Biol Sci Med Sci. 2001;56(4):M217-M225.
17. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279(8):585-592.
18. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991;67(4): 295-299.
19. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol. 1996;77(10):864-866.
20. Vokonas PS, Kannel WB. Epidemiology of coronary heart disease in the elderly. In: Aronow WS, Fleg JL, Rich MW, eds. Cardiovascular Disease in the Elderly. 4th ed. New York, NY: Informa Healthcare; 2008:215-241.
21. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9): 1245-1249.
22. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med. 2001;161(9):1183-1192.
23. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57(20):2037-2114.
24. Aronow WS, Ahn C, Gutstein H. Risk factors for new atherothrombotic brain infarction in 664 older men and 1,488 older women. Am J Cardiol. 1996;77(15):1381-1383.
25. Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep. 2004;6(2):124-129.
26. Wolf PA. Cerebrovascular disease in the elderly. In: Tresch DD, Aronow WS, eds. Cardiovascular Disease in the Elderly Patient. New York, NY: Marcel Dekker, Inc.; 1994:125-147.
27. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84(5):611-612, A9.
28. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562.
29. Stokes J 3rd, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation. 1987;75(6 pt 2):V65-V73.
30. Aronow WS, Sales FF, Etienne F, Lee NH. Prevalence of peripheral arterial disease and its correlation with risk factors for peripheral arterial disease in elderly patients in a long-term health care facility. Am J Cardiol. 1988;62(9):644-646.
31. Ness J, Aronow WS, Ahn C. Risk factors for peripheral arterial disease in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48(3):312-314.
32. Ness J, Aronow WS, Newkirk E, McDanel D. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci. 2005;60(2):255-257.
33. Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensity-matched study of the association of peripheral arterial disease with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103(1):130-135.
34. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001; 345(7):479-486.
35. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466-472.
36. Gandelman G, Aronow WS, Varma R. Prevalence of adequate blood pressure control in self-pay or Medicare patients versus Medicaid or private insurance patients with systemic hypertension followed in a university cardiology or general medicine clinic. Am J Cardiol. 2004;94(6):815-816.
37. The Australian Therapeutic Trial in Mild Hypertension. Report by the Management Committee. Lancet. 1980;1(8181):1261-1267.
38. MRC trial of mild hypertension: principal results. Medical Research Council Working Party. Br Med J. 1985;291(6488):97-104.
39. Medical Research Council Trial of treatment of hypertension in older adults: principal results. MRC Working Party. Br Med J. 1992;304(6824):405-412.
40. Amery A, Birkenhäger W, Brixko P, et al. Morbidity and mortality results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;1(8442):1349-1354.
41. Coope J, Warrender TS. Randomised trial of the treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145-1151.
42. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-1285.
43. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-3264.
44. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278(3):212-216.
45. Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284(4):465-471.
46. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764.
47. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160(2):211-220.
48. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008;358(18):1887-1898.
49. Aronow WS, Frishman WH. Effect of antihypertensive drug treatment on cognitive function. Clin Geriatr. 2006;14:25-28.
50. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041.
51. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046-2052.
52. Murray MD, Lane KA, Gao S, et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med. 2002;162(18):2090-2096.
53. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001; 22(3):407-412.
54. Aronow WS. What is the appropriate treatment of hypertension in elders? J Gerontol A Biol Sci Med Sci. 2002;57(8):M483-M486.
55. Goodwin JS. Embracing complexity: a consideration of hypertension in the very old. J Gerontol A Biol Sci Med Sci. 2003;58(7): 653-658.
56. Aronow WS. Older age should not be a barrier to the treatment of hypertension. Nat Clin Pract Cardiovas Med. 2008;5(9):514-515.
57. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8(1): 13-28.
58. Aronow WS. Hypertension guidelines. Hypertension. 2011;58(3): 347-348.
59. Banach M, Michalska M, Kjeldsen SE, Malyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12(12):1835-1844.
60. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121(7-8):253-258.
61. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly [published online ahead of print October 13, 2011]. Blood Press.
62. Banach M, Aronow WS. Hypertension therapy in the elderly-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Hum Hypertens. In press.
63. Webster JL, Dunford EK, Hawkes C, Neal BC. Salt reduction initiatives around the world. J Hypertens. 2011;29(6):1043-1050.
64. Frohlich ED, Susic D. Sodium and its multiorgan targets. Circulation. 2011;124(7):1882-1885.
65. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885-888.
66. Mancia G, Laurent S, Agabiti-Rosei E, et al; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;27(11):2121-2158.
67. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;339:b1665.
68. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 2003;362(9384):591-592.
69. Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364(9446):1684-1689.
70. Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacotherap. 2010;11(16):2599-2607.
71. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719-2728.
72. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
73. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
74. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347(16):1256-1261.
75. Hricick DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med. 1983;308(7):373-376.
76. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med. 1991;115(7): 513-519.
77. Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761-2788.
78. Pahor M, Guralnik JM, Corti C, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 1995;43(11):1191-1197.
79. Aronow WS. Verapamil as an antiarrhythmic agent. In: Gould LA, ed. Drug Treatment of Cardiac Arrhythmias. Mount Kisco, NY: Futura Publishing Company, Inc.; 1983:325-341.
80. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385-392.
81. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52-60.
82. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol. 2002;89(10):1207-1209.
83. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82(6):1954-1961.
84. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15): 1967-1975.
85. Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow WS, Fleg JL, Rich MW, eds. Cardiovascular Disease in the Elderly. 4th ed. New York, NY: Informa Healthcare; 2008:99-135.
86. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed). 1984;289(6442):410-412.
87. Krehlik JM, Hindson DA, Crowley JJ, Knight LL. Minoxidilassociated pericarditis and fatal cardiac tamponade. West J Med. 1985;143(4):527-529.
88. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100(9): 1016-1030.
89. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3): 145-153.
90. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 2001;88(11): 1298-1300.
91. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol. 2001;87(6):780-781.
92. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87(11):1284-1286.
93. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1994;74(7):674-680.
94. Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients. or = 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction. or = 40%. Am J Cardiol. 1994;74(3): 267-270.
95. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
96. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-225.
97. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction. or = 40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol. 1997;80(2):207-209.
98. Aronow WS, Frishman WH. Angina in the elderly. In: Aronow WS, Fleg JL, Rich MW, eds. Cardiovascular Disease in the Elderly. 4th ed. New York, NY: Informa Healthcare; 2008:269-292.
99. Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol. 1994;74(6):613-615.
100. Aronow WS. Etiology, pathophysiology, and treatment of atrial fibrillation: part 1. Cardiol Rev. 2008;16(4):181-188.
101. Aronow WS. Treatment of atrial fibrillation and atrial flutter: part II. Cardiol Rev. 2008;16(5):230-239.
102. Aronow WS. The heart and thyroid disease. In: Gambert SR, ed. Clinics in Geriatric Medicine. Thyroid Disease. Philadelphia, PA: W. B. Saunders; 1995:219-229.
103. Hunt SA, Baker DW, Chin MH, et al; American College of Cardiology/ American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38: 2101-2113.
104. Smith SC Jr, Allen J, Blair SN, et al; AHA/ACC; National Heart, Lung, and Blood Institute. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
105. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
106. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S33-S50.
107. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321(7258):405-412.
108. Ravipati G, Aronow WS, Ahn C, Sujata K, Saulle LN, Weiss MB. Association of hemoglobin A(1c) level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol. 2006;97(7):968-969.
109. Aronow WS, Ahn C, Weiss MB, Babu S. Relation of hemoglobin A(1c) levels to severity of peripheral arterial disease in patients with diabetes mellitus. Am J Cardiol. 2007;99(10):1468-1469.
110. Bangalore S, Qin J, Sloan S, et al; PROVE-IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and car diovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122(21):2142-2151.
111. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-68.
112. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
113. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107(8):1208-1214.
114. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124(16):1727-1736.
115. Guichard JL, Desai RV, Ahmed MI, et al. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011;58(5):895-901.